THEMIS MEDICARE LTD.

Themis Medicare Ltd has announced that the Board of Directors has fixed Wednesday, September 23, 2026, as the record date for determining shareholder entitlement to dividends for the financial year ended March 31, 2026. This dividend is subject to approval by the shareholders at the 56th Annual General Meeting scheduled for Wednesday, September 30, 2026. The company has complied with SEBI Listing Regulations by making this disclosure.

Themis Medicare Ltd has filed its Annual Report for the financial year ended March 31, 2026, along with the notice for its 56th Annual General Meeting (AGM). The AGM is scheduled for September 30, 2026, at the company's registered office in Vapi, Gujarat. The report details the company's performance, strategic initiatives across its Formulations, API, and Hospital businesses, and includes management discussions, corporate governance, and sustainability reports. Key personnel changes, including the cessation of Director – Legal, Compliance & Company Secretary and appointment of an Interim Company Secretary, are also noted.

Themis Medicare Ltd has filed its Annual Report for the financial year ended March 31, 2026, along with the notice for its 56th Annual General Meeting (AGM). The AGM is scheduled for September 30, 2026, at the company's registered office in Vapi, Gujarat. The report details the company's performance, strategic initiatives, and future outlook, emphasizing a focus on innovation, operational excellence, and market leadership in the pharmaceutical sector. Key areas of discussion include the restructuring of the Formulations business, growth in the API and Hospital businesses, and performance of the Trade Business. The report also outlines the Board of Directors and statutory information.

Themis Medicare Ltd has filed its Annual Report for the financial year ended March 31, 2026, along with the Notice for its 56th Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 30, 2026, at 11:00 AM at the company's registered office in Vapi, Gujarat. The report details the company's performance, strategic initiatives across its Formulations, API, and Hospital businesses, and outlines plans for future growth. The company aims to become a leading research-based pharmaceutical entity, focusing on high-quality manufacturing and strategic partnerships.

Themis Medicare Ltd has designated authorized personnel to determine the materiality of events or information and to make necessary disclosures to stock exchanges as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The authorized individuals include the Executive Chairman, Managing Director & CEO, Company Secretary & Compliance Officer, and Chief Financial Officer. Mr. Suresh Savaliya, Company Secretary & Compliance Officer, is designated as the single point of contact for these disclosures.

Themis Medicare Ltd announced its Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The Board of Directors also approved the resignation of Mr. Nagraj Mogaveera as Interim Company Secretary & Compliance Officer and the appointment of Mr. Suresh Savaliya as the new Company Secretary, Compliance Officer & Key Managerial Personnel (KMP). The board meeting commenced at 10:30 AM IST and concluded at 12:45 PM IST.

Consolidated PAT for Q1 FY27 was ₹24.61 Cr (EPS ₹2.67 basic) against a ₹14.22 Cr loss in Q1 FY26 — a reported turnaround, but the entire swing owes to a ₹92.95 Cr exceptional gain booked on the sale of 24.97 lakh shares in associate Gujarat Themis Biosyn Ltd for ₹100 Cr consideration (approved by the board on 13 Feb 2026 and shareholders on 27 Mar 2026). Strip that one-off out and the underlying business posted an adjusted net loss of roughly ₹68 Cr, deeper than the ₹14.22 Cr loss a year ago — so this is not a turnaround on an adjusted basis, it is a widening core loss dressed up by an asset sale. Standalone PAT was ₹28.74 Cr (EPS ₹3.12); consolidated is the primary read. Revenue from operations fell 10.9% YoY to ₹86.96 Cr (₹97.58 Cr in Q1 FY26) while total expenses rose 28.6% YoY to ₹144.90 Cr (₹112.68 Cr), pushing the core pretax loss (before exceptional items and associate income) to ₹56.95 Cr from ₹13.93 Cr — roughly 4x wider. The expense growth was concentrated in purchases of stock-in-trade, up 129.8% YoY to ₹49.81 Cr, and other expenses, up 94.7% to ₹59.21 Cr, even as employee costs fell 10.7% to ₹22.18 Cr. The filing's notes do not explain the jump in trading purchases and other expenses, so the driver behind the cost spike is not disclosed here. No management press release or MD&A accompanies this filing, and the notes attribute the exceptional gain solely to the Gujarat Themis Biosyn stake sale with no further commentary on the core business. There is no prior management guidance on record, and no analyst/street consensus was found for this print (Themis Medicare carries no visible dedicated brokerage coverage) — both vsGuidance and vsStreet are unknown. Standalone and consolidated PAT diverge by about 17% (₹28.74 Cr vs ₹24.61 Cr): standalone books the full ₹99.67 Cr stake-sale gain while consolidated additionally includes ₹2.59 Cr of share of associate/JV profit. The quarter also saw a Company Secretary transition (Nagraj Mogaveera resigned, Suresh Savaliya appointed w.e.f. 13 Aug 2026) and a series of promoter share-pledge/release/encumbrance disclosures between 21 Jul and 5 Aug 2026 — none of which bear directly on the P&L. With the one-off gain now booked, the ₹100 Cr in sale proceeds sits alongside a core business running at a ₹56.95 Cr quarterly pretax loss; the next print's core-loss trajectory — and whether the elevated trading-purchase/other-expense run-rate persists — is the key thing to track, since no further stake sale of this size is flagged to repeat the cushion.

CTL Trusteeship Limited, acting as debenture trustee, has disclosed the creation of an encumbrance on 30,00,000 equity shares of Themis Medicare Limited. This pledge, effective July 31, 2026, is in favor of CTL Trusteeship on behalf of debenture holders, as per a debenture trust deed with OSS Software Solutions Labs Private Limited. The encumbered shares represent 3.26% of Themis Medicare's total diluted share capital. Following this, the total encumbered shares held by Vividhmargi Trust (in whose name the shares are registered) in favor of the debenture trustee now stand at 2,83,17,620, representing 30.75% of the total diluted share capital.

Themis Medicare Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda for this meeting is to consider and approve the Standalone and Consolidated Un-Audited Financial Results for the quarter ending June 30, 2026, along with the Limited Review Reports from the Statutory Auditors. Additionally, the company has informed its 'Designated Persons' about the closure of the Trading Window from July 1, 2026, until 48 hours after the publication of these financial results, in compliance with SEBI's Insider Trading Regulations.

Vividhmargi Investments Pvt Ltd, a promoter of Themis Medicare Ltd, has disclosed the pledge of 30,00,000 equity shares, representing 3.26% of the total share capital. This encumbrance was created on July 30, 2026, as security for borrowings from Kotak Credit Opportunities Fund, with CTL Trusteeship Limited acting as the trustee. The disclosure is made in accordance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Following this event, Vividhmargi Investments Pvt Ltd's direct promoter holding in Themis Medicare remains at 2,44,29,460 shares, constituting 26.52% of the total share capital, with no shares already encumbered prior to this transaction.